The ABLATE PAS demonstrates durable Afib freedom across 3 years.
 
Consistent with the ABLATE IDE Trial, these findings reinforce the long-term effectiveness and durability of surgical ablation in a real-world patient population. Learn more about the study:

The LAA is more than a source of stroke risk—it can also contribute to the electrical activity that sustains Afib. Durable LAA exclusion with electrical isolation may help support rhythm stabilization and a return to sinus rhythm as part of a more complete strategy.

1 in 3 people having cardiac surgery already have Afib.

Afib is a common heart rhythm condition that can increase the risk of stroke and other complications—but many people don’t even realize they have it.

Learn more about Afib symptoms and when to talk to your doctor at: <a href="https://www.facebook.com/hashtag/https://oktto/XfTDs0

Afib" target="_blank">https://okt.to/XfTDs0

#Afib</a> <a href="https://www.facebook.com/hashtag/AtrialFibrillation&quot; target="_blank">#AtrialFibrillation</a> <a href="https://www.facebook.com/hashtag/AfibAwareness&quot; target="_blank">#AfibAwareness</a>

Stroke risk remains a consequence of untreated Afib. During Stroke Awareness Month, addressing Afib during cardiac surgery—through surgical ablation and LAA management—may help reduce stroke risk and improve long-term outcomes. Treat the rhythm. Change the trajectory. Learn more:

Cardiovascular disease is the leading cause of death among women, but the American Heart Association is working to change that. AtriCure is proud to support the AHA and their ongoing efforts in heart health research, education, and community programs, including the Heart Walk, CycleNation, Heart Ball, and the recent Go Red for Women Experience in Cincinnati. <a href="https://www.facebook.com/hashtag/
AHA" target="_blank">
#AHA</a> <a href="https://www.facebook.com/hashtag/AmericanHeartAssociation&quot; target="_blank">#AmericanHeartAssociation</a>

In the ICE-AFIB Trial, patients who received concomitant Cox-Maze III lesions using the cryoICE cryoFORM® Cryoablation probe during cardiac surgery experienced improvements in quality of life.*

Another quarter, another step forward. Our Q1 results highlight the impact of our strategy in action.

Read the full earnings report: <a href="https://t.co/NIzAWdN4fk&quot; target="_blank">https://t.co/NIzAWdN4fk</a&gt;
 
<a href="https://twitter.com/hashtag/Earnings?src=hashtag_click&quot; target="_blank">#Earnings</a> <a href="https://twitter.com/hashtag/FinancialResults?src=hashtag_click&quot; target="_blank">#FinancialResults</a>

<a href="https://twitter.com/hashtag/AATS2026?src=hashtag_click&quot; target="_blank">#AATS2026</a> was one for the books. Through our CME symposium and exhibit floor conversations, we connected with surgeons to discuss the AtriClip portfolio for LAAE, its use with the EnCompass clamp in a single &amp; the cryoSPHERE® MAX probe for post-op pain management. Thanks for

In exclusion, confidence comes from completeness.

AtriClip’s straight profile is engineered for full tissue capture and uniform compression—delivering complete, reliable closure and the durable exclusion clinicians expect and patients deserve. 

Learn more:

The ABLATE Post-Approval Study required all surgeons to complete AtriCure training—showing durable Afib outcomes aren’t limited to a few.

With Synergy RF technology, consistent, real-world results are achievable for trained surgeons.

Learn more: <a href="https://t.co/RoNB846poE&quot; target="_blank">https://t.co/RoNB846poE</a&gt;